Insmed reported $531.05M in Equity Capital and Reserves for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Equity Capital And Reserves Change
Acelrx Pharmaceuticals ACRX:US $ -35.99M 8.68M
Alexion Pharmaceuticals ALXN:US $ 12416.8M 765.6M
Arena Pharmaceuticals ARNA:US $ 971.08M 114.91M
Biomarin Pharmaceutical BMRN:US $ 4241.57M 79.56M
Cytokinetics CYTK:US $ 16.49M 51.36M
Dynavax Technologies DVAX:US $ 83.38M 16.38M
Flexion Therapeutics FLXN:US $ -56171000 17.3M
Gilead Sciences GILD:US $ 19710M 758M
Heron Therapeutics HRTX:US $ 160.11M 36.11M
Insmed INSM:US $ 531.05M 329.42M
Mirati Therapeutics MRTX:US $ 1128.92M 130.49M
Novartis NVS:US $ 54042M 3519M
Regeneron Pharmaceuticals REGN:US $ 15127.3M 3150.3M
Sarepta Therapeutics SRPT:US $ 485.11M 50.34M
Seattle Genetics SGEN:US $ 3391.27M 33.35M
Ultragenyx Pharmaceutical RARE:US $ 972.17M 82.41M
Vertex Pharmaceuticals VRTX:US $ 9196.4M 216.14M